|
Mar 21
|
Alnylam Gets FDA Nod for Expanded Use of Amvuttra in Cardiomyopathy
|
|
Mar 21
|
Pharma Stock Roundup: PFE's Final Haleon Stake Sale, AZN, SNY M&A Deals
|
|
Mar 21
|
FDA Approves Expanded Use Of Novartis Rare Disease Drug As Only Treatment For Rare Type Of Kidney Disease
|
|
Mar 21
|
AstraZeneca deepens China investment; Editas loses CFO to Dyne
|
|
Mar 20
|
Novartis receives third FDA approval for oral Fabhalta® (iptacopan) - the first and only treatment approved in C3 glomerulopathy (C3G)
|
|
Mar 20
|
Novartis Reports Updated Positive Data From Phase III SMA Program
|
|
Mar 20
|
Novartis builds case for new SMA gene therapy
|
|
Mar 20
|
Novartis reports Phase III efficacy and safety outcomes of SMA treatment
|
|
Mar 20
|
Teen’s death following Sarepta DMD gene therapy underscores a risk seen for decades
|
|
Jan 31
|
Novartis Pares Gains As Its Bread-And-Butter Drug Faces Looming Competition
|
|
Jan 31
|
Novartis Ag (NVS) Q4 2024 Earnings Call Transcript
|
|
Jan 31
|
Novartis (NVS) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
|
|
Jan 31
|
Health Care Roundup: Market Talk
|
|
Jan 31
|
Novartis sets ‘ambitious’ target; Skyrizi, Rinvoq sales climb
|
|
Jan 31
|
Novartis Q4 Earnings: Revenue And EPS Beat, CEO Dismisses Entresto Patent Expiration Worries
|
|
Jan 31
|
Trending tickers: Apple, Intel, Novartis, Shell, Smiths Group
|
|
Jan 31
|
Novartis: Q4 Earnings Snapshot
|
|
Jan 31
|
Novartis Expects Further Profit, Sales Growth Despite Competition Threat
|
|
Jan 31
|
Novartis beats Q4 earnings consensus as drug sales surge
|
|
Jan 31
|
Novartis continues strong momentum of sales growth with margin expansion, reaches key innovation milestones in 2024
|